澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MESOBLAST LTD

2.140

+0.1105.42%

成交量：460.70萬

成交額：977.91萬

市值：27.61億

市盈率：-20.91

高：2.140

開：2.040

低：2.030

收：2.030

52周最高：3.310

52周最低：1.527

股本：12.90億

流通股本：7.86億

量比：2.54

換手率：0.59%

股息：- -

股息率：- -

每股收益(TTM):-0.102

每股收益(LYR):-0.118

淨資產收益率：-18.22%

總資產收益率：-6.16%

市淨率：3.45

市盈率(LYR):-18.19

資料載入中...

總覽公司新聞資訊公告

Mesoblast公布Ryoncil®季度淨收入達3030萬美元運營現金流支出改善至410萬美元

異動解讀 | Mesoblast收購CAR平台技術，盤中大漲5.22%

Mesoblast收購嵌合抗原受體平台技術，推動精準增強型細胞產品發展

Mesoblast獲FDA批准可直接開展Ryoncil®治療杜氏肌營養不良症的註冊試驗

異動解讀 | Mesoblast公布上半年業績虧損4020萬美元，股價盤中大跌7.23%

Mesoblast公布上半年總收入5130萬美元

異動解讀 | Mesoblast核心產品收入預期樂觀，股價盤中大漲5.79%

Mesoblast Limited預計2026財年Ryoncil淨收入將達1.1億至1.2億美元

FDA確認Rexlemestrocel-L在疼痛強度上展現積極效果，12個月背痛減輕數據支持產品療效

獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨床效果上優於Ruxolitinib

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MSB.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.14,"timestamp":1780035120000,"preClose":2.03,"halted":0,"volume":4606991,"delay":0,"changeRate":0.054187192118226764,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.10234353268428374,"marketStatus":"休市中","change":0.11,"latestTime":"05-29 16:12:00 AEST","open":2.04,"high":2.14,"low":2.03,"amount":9779061,"amplitude":0.054187,"askPrice":2.14,"askSize":7418,"bidPrice":2.13,"bidSize":3317,"shortable":3,"etf":0,"ttmEps":-0.10234353268428374,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1780272000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.03,"openAndCloseTimeList":[[1780012800000,1780034400000]],"volumeRatio":2.535728132649012,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.03,"auctionPrice":2.14,"auctionVolume":2439575,"auction":3,"marketStatus":"盘后竞价","timestamp":1780035000622}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.11762,"volumeRatio":2.535728132649012,"shares":1290302187,"dividePrice":0,"high":2.14,"amplitude":0.054187,"preClose":2.03,"low":2.03,"week52Low":1.527,"pbRate":"3.45","psRate":"30.36","week52High":3.31,"institutionHeld":0,"latestPrice":2.14,"committee":-0.382021,"eps":-0.10234353268428374,"divideRate":0,"volume":4606991,"delay":0,"ttmEps":-0.10234353268428374,"open":2.04,"prevYearClose":2.72,"prevWeekClose":2.12,"prevMonthClose":2.12,"prevQuarterClose":2.16,"fiveDayClose":2.12,"twentyDayClose":2.2,"sixtyDayClose":2.02,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170600195","title":"Mesoblast公布Ryoncil®季度淨收入達3030萬美元 運營現金流支出改善至410萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170600195","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170600195?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 08:55","pubTimestamp":1777510516,"startTime":"0","endTime":"0","summary":"生物技术公司Mesoblast Limited（ASX: MSB）最新财报显示，其旗舰产品Ryoncil®在本季度实现净收入3030万美元。与此同时，公司净运营现金支出显著优化，降至410万美元水平。\n财务数据显示，Mesoblast通过精细化运营管理有效控制了成本支出。该公司在保持核心产品收入稳定增长的同时，实现了运营效率的持续提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","LU2264538146.SGD","LU1988902786.USD","LU1093756325.SGD","BK4588","BK7501","SG9999002224.SGD","BK4512","LU1894683264.USD","MMM","LU0683600562.USD","BK4206","MSB.AU","BK7067","LU1894683348.USD","LU0787776722.HKD","LU1093756168.USD","BK7508","LU1064131342.USD","SG9999002232.USD","BK4533","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188850121","title":"異動解讀 | Mesoblast收購CAR平台技術，盤中大漲5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188850121","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188850121?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:19","pubTimestamp":1776212364,"startTime":"0","endTime":"0","summary":"细胞疗法研发企业MESOBLAST LTD（MSB.AU）今日盘中股价大幅上涨5.22%，引起市场关注。消息面上，公司宣布成功收购嵌合抗原受体（CAR）平台技术，该技术将显著提升其细胞产品的精准治疗能力，标志着公司在细胞治疗领域的重大战略布局。通过此次收购整合CAR技术平台，Mesoblast有望开发出更具靶向性和疗效的下一代细胞疗法产品，从而强化其在肿瘤免疫治疗领域的竞争力，为患者提供更精准的个性化治疗方案。这一利好消息直接提振了市场对公司未来发展的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180289197","title":"Mesoblast收購嵌合抗原受體平台技術，推動精準增強型細胞產品發展","url":"https://stock-news.laohu8.com/highlight/detail?id=1180289197","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180289197?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:11","pubTimestamp":1776211877,"startTime":"0","endTime":"0","summary":"细胞疗法研发企业MESOBLAST LTD宣布成功收购嵌合抗原受体（CAR）平台技术，该技术将显著提升其细胞产品的精准治疗能力。\n此次收购标志着公司在细胞治疗领域的重大战略布局，通过整合CAR技术平台，有望开发出更具靶向性和疗效的下一代细胞疗法产品。\n该技术平台的引入将强化MESOBLAST LTD在肿瘤免疫治疗领域的竞争力，为患者提供更精准的个性化治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129617691","title":"Mesoblast獲FDA批准 可直接開展Ryoncil®治療杜氏肌營養不良症的註冊試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1129617691","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129617691?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 11:37","pubTimestamp":1775619420,"startTime":"0","endTime":"0","summary":"Mesoblast Limited (ASX: MSB) 已获得美国食品药品监督管理局（FDA）的研究性新药（IND）许可，获准直接推进其核心产品Ryoncil®（瑞洛西尔）用于治疗杜氏肌营养不良症（DMD）的注册临床试验。\n此项关键性监管绿灯意味着，公司无需再进行额外的早期临床研究，即可启动旨在支持该疗法最终上市申请的注册试验阶段。此举显著加快了Ryoncil®针对这一严重遗传性肌肉疾病的开发进程，为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127354637","title":"異動解讀 | Mesoblast公布上半年業績虧損4020萬美元，股價盤中大跌7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127354637","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127354637?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 10:22","pubTimestamp":1772158948,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 今日盘中股价大跌7.23%，引起了市场的广泛关注。消息面上，公司公布了上半年的财务业绩，虽然总收入达到5130万美元，但归属于公司的亏损高达4020万美元。这一显著的亏损数据可能引发了投资者对公司盈利能力和财务状况的担忧，从而导致股价在交易时段内出现大幅下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171017622","title":"Mesoblast公布上半年總收入5130萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171017622","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171017622?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 10:15","pubTimestamp":1772158552,"startTime":"0","endTime":"0","summary":"2月27日（路透社）—— Mesoblast Ltd 发布中期业绩公告：*上半年总收入达5130万美元* *归属于公司亏损为4020万美元*\n更多公司相关报道可参考股票代码MSB.AX。\n（信息来源：路透社简报；发布时间：2026年2月27日02:03:10 GMT）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164807609","title":"異動解讀 | Mesoblast核心產品收入預期樂觀，股價盤中大漲5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164807609","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164807609?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 07:03","pubTimestamp":1772146980,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 今日盘中大涨5.79%，引起了市场的广泛关注。消息面上，Mesoblast Limited预计其核心产品Ryoncil在2026财年的全年净收入将介于1.1亿美元至1.2亿美元之间，这一积极的财务预期反映了公司对产品商业化前景的信心，可能提振了投资者情绪。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110626132","title":"Mesoblast Limited預計2026財年Ryoncil淨收入將達1.1億至1.2億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110626132","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110626132?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 05:53","pubTimestamp":1772142784,"startTime":"0","endTime":"0","summary":"生物技术企业Mesoblast Limited最新预测显示，其核心产品Ryoncil在2026财年的全年净收入预计将介于1.1亿美元至1.2亿美元之间。这一预期反映了公司对产品商业化前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","MSB.AU","BK7067","BK7508","BK7501","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118834527","title":"FDA確認Rexlemestrocel-L在疼痛強度上展現積極效果，12個月背痛減輕數據支持產品療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118834527","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118834527?lang=zh_tw&edition=fundamental","pubTime":"2026-01-19 08:02","pubTimestamp":1768780936,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式认可Rexlemestrocel-L在缓解疼痛强度方面表现出显著优势。最新数据显示，该疗法在12个月内持续减轻背痛的效果，进一步验证了其临床有效性。这一进展为MESOBLAST LTD旗下产品的应用前景提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7508","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100916668","title":"獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨床效果上優於Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1100916668","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100916668?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 07:26","pubTimestamp":1765495606,"startTime":"0","endTime":"0","summary":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}